The shares of InnoMedica Holding AG (Valor: 55,897,390; ISIN: CH0558973902) are registered shares, which are electronically booked into the shareholder’s respective securities account. InnoMedica shares are not listed on the stock exchange but are freely tradable. There are 19,053,034 shares outstanding (with a nominal value of CHF 0.10 each). Since they are registered shares, shareholders must be entered in the share register to exercise their voting rights. For this, the shareholder must provide authorization to their bank. Depending on the bank, this may need to be done again with each new share purchase.

Shares can be subscribed during a capital increase, which enables investment in InnoMedica to drive the progress of its projects. Since 2013, InnoMedica has conducted annual capital increases, expanding its shareholder base to over 1,600 shareholders, and raising a total of approximately CHF 87.5 million in capital. By submitting the completed subscription form and depositing the corresponding amount, share subscriptions will be considered in the allocation process after the completion of the capital increase. A minimum subscription amount, as specified in the capital increase, must be adhered to.

Outside of capital increases, InnoMedica offers interested buyers the opportunity to place a purchase request through an OTC (over the counter) trading platform. If a matching transaction can be made, InnoMedica will assist in the execution of the share purchase, subject to an administrative fee. In this case, the payment does not flow into the company.

InnoMedica offers shareholders who do not have their own bank securities account the option to hold shares directly with the company. This service is currently provided free of charge. At the end of each year, as well as in the event of changes to the shareholding, InnoMedica issues a confirmation of the current share ownership. It is the responsibility of shareholders to notify the company of any changes to their personal details directly.

For non-listed companies without income, the tax value is calculated based on the net asset value (gross), with a flat deduction of 30% (net). This value is significantly lower than the share value, as the latter considers the company’s projected development. Since the financial statements audited are not available by December 31st, the net asset value is calculated based on the previous year’s figures.

The main shareholders of InnoMedica are the Halbherr, Yamazaki, Früh and Bron families. Together, in a shareholder pool, they control 26,4% of the company’s shares.

An initial public offering (IPO) must always be evaluated in the context of the broader economic situation, regardless of the company. Recently, companies in the biotech sector with public listings have had to stay resilient, facing extremely challenging circumstances. However, the market situation is not the only condition that must be met for an IPO. If the following additional conditions are satisfied, InnoMedica plans to proceed with an IPO:

• Risk Profile: An IPO would substantially expand InnoMedica’s shareholder base. The large number of Swiss and international shareholders, as well as the involvement of institutional investors, places higher demands on stability, track record, profitability, and remaining development risks. Meeting these criteria will result in a higher company valuation. Any limitations in meeting these requirements will lead to higher valuation discounts.
  
• Costs: A stock market listing involves substantial administrative and financial costs. These expenses should ideally be covered by early operational revenues, rather than being funded by the risk capital of early investors.
  

InnoMedica prepares the annual report for the previous year during the first half of each year and provides it to shareholders in both electronic and physical formats. Through the annual capital increases, InnoMedica also prepares a business plan, which informs investors and interested parties about milestones that have been achieved and those yet to come. The business plan also includes information on financial planning and future steps, contingent on the full subscription of the capital increase. Additionally, InnoMedica communicates relevant milestones related to the achievement of corporate goals to shareholders via the shareholder newsletter.